ArticleCell communication and signaling : CCS2025
Hypo-glycosylated FSH enhances the ovarian microenvironment for follicular development compared to fully glycosylated FSH.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Differential N-glycosylations of follicle-stimulating hormone (FSH) influence follicular development dynamics, significantly affecting assisted reproductive technology outcomes. However, the ovarian microenvironment induced by different FSH glycoforms remains incompletely understood. In this study, in vivo analyses using RT-qPCR, single-cell RNA sequencing, and bulk RNA sequencing demonstrated that FSH administration rapidly activated responses in both granulosa cells (GCs) and theca cells (TCs) within 2 h. Hypo-glycosylated FSH (hgFSH) initiated GCs and TCs differentiation more effectively than fully glycosylated FSH (fgFSH), and genes with higher expression in hgFSH were predominantly located in these cell types. HgFSH significantly upregulated 20.2% of total ovarian ligand genes, suggesting a more actively ovarian communicating microenvironment. In contrast, fgFSH inhibited the expression of oocyte-specific ligands such as Bmp15, Gdf9 and Oosp1, potentially disrupting oocytes-GCs communication. More importantly, hypo-glycosylated FSH upregulated genes significantly enriched in TCs. HgFSH activated key biological pathways in TCs such as lipid metabolic process and enhanced communication between GCs and TCs through more interactions than fgFSH. Our findings suggest that hgFSH fosters a more effective ovarian microenvironment for follicular development compared to fgFSH, highlighting the potential clinical benefits of hgFSH applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.